ClinicalTrials.gg
CompletedNCT02335983Updated Nov 6, 2020Results posted

Phase 1b Study of Weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma

A Phase 1 interventional study of Carfilzomib and Lenalidomide in Multiple Myeloma, sponsored by Amgen. Completed at 59 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-06.

Sponsored by Amgen · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
107
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 113 studies testing carfilzomib in Multiple Myeloma — 14 open to participants now, 39 under way, 7 of them phase 3. carfilzomib · Multiple Myeloma.

Enrollment
26th of 113
107 · median 54
Started
2015
with 1 other
Phase 1
17 of 113
2 open now
Registered
54th of 113
by date
Lead sponsor
21 of 113
Amgen

Among the 113 studies testing carfilzomib in Multiple Myeloma, this one is the 26th largest by enrollment, is one of 2 that started in 2015, is one of 17 in phase 1, and was the 54th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

14 of the 113 studies testing carfilzomib in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About carfilzomib

carfilzomib: first FDA approval 2012 (KYPROLIS), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies testing carfilzomib in Multiple Myeloma, or all of them as a file.
02

Study summary

The purpose of the study is to assess the safety, tolerability and activity of a once-weekly regimen of carfilzomib in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Newly diagnosed or multiple myeloma
  2. Measureable disease by serum M protein, or urine M protein, or serum free light chain (SFLC) and an abnormal serum kappa lambda ratio (for subjects without detectable serum or urine M-protein), or serum quantitative immunoglobulin A (glgA) (for immunoglobulin (Ig) A subjects whose disease can only be reliable measured by qlgA).
  3. (ECOG) Performance Status (PS) of 0 to 2
  4. (LVEF) ≥ 40%

Key Exclusion Criteria:

  1. Waldenström macroglobulinemia
  2. For newly diagnosed multiple myeloma: multiple myeloma of IgM subtype
  3. For relapsed disease:

    1. If treated with a lenalidomide and dexamethasone combination, progression during the first 3 months after initiating treatment.
    2. Any progression during treatment if the lenalidomide and dexamethasone regimen was the most recent .
    3. Any prior treatment with carfilzomib
  4. POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)
  5. Plasma cell leukemia (> 2.0 × 10\^9/L circulating plasma cells by standard differential)
  6. Myelodysplastic syndrome
  7. Amyloidosis
  8. Prior treatment with carfilzomib or oprozomib
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
107 participants (actual)

Study arms

  • Experimental
    RRMM Dose-evaluation: Carfilzomib 56 mg/m²

    Participants with relapsed or refractory multiple myeloma (RRMM) received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death. Participants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 56 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8.

    Drug: Carfilzomib · Drug: Lenalidomide · Drug: Dexamethasone

  • Experimental
    RRMM Dose-evaluation: Carfilzomib 70 mg/m²

    Participants with RRMM received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death. Participants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 70 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8.

    Drug: Carfilzomib · Drug: Lenalidomide · Drug: Dexamethasone

  • Experimental
    RRMM Dose-expansion: Carfilzomib 70 mg/m²

    Participants with RRMM received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death. Participants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 70 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8.

    Drug: Carfilzomib · Drug: Lenalidomide · Drug: Dexamethasone

  • Experimental
    NDMM Dose-evaluation: Carfilzomib 56/70 mg/m²

    Participants with newly diagnosed multiple myeloma (NDMM) received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death. Participants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1 day 1, 56 mg/m² on cycle 1 days 8 and 15, and then 70 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8.

    Drug: Carfilzomib · Drug: Lenalidomide · Drug: Dexamethasone

  • Experimental
    NDMM Dose-expansion: Carfilzomib 70 mg/m²

    Participants with NDMM received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death. Participants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 70 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8.

    Drug: Carfilzomib · Drug: Lenalidomide · Drug: Dexamethasone

  • Experimental
    NDMM Dose-expansion: Carfilzomib 56 mg/m²

    Participants with NDMM received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death. Participants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 56 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8.

    Drug: Carfilzomib · Drug: Lenalidomide · Drug: Dexamethasone

Interventions

  • Administered once weekly by 30-minute intravenous (IV) infusion on days 1, 8, and 15 of each 28-day cycle.

    Also known as: PR-171, PR171, Kyprolis® (carfilzomib) for Injection

  • Administered orally once daily on days 1-21 of each 28-day cycle.

    Also known as: Revlimid®

  • Administered by mouth or IV at 40 mg on days 1, 8, and 15 of each 28-day cycle and on day 22 of cycles 1 to 8.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs)

    Safety and tolerability were evaluated according to the type, incidence, and severity of adverse events. An AE is defined as any untoward medical occurrence in a clinical trial subject. The event does not necessarily have a causal relationship with study treatment. A serious adverse event is defined as an AE that meets at least 1 of the following serious criteria: * fatal * life threatening * requires in-patient hospitalization or prolongation of existing hospitalization * results in persistent or significant disability/incapacity * congenital anomaly/birth defect * other medically important serious event The severity of each AE was assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03 where Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life-threatening, and Grade 5 = Death.

    Time frame: From the first dose of any study drug up to 30 days after the last dose of any study drug; median (range) duration of treatment with carfilzomib was 32 (1.1, 76.7) weeks in RRMM participants and 26 (1.0, 94.4) weeks in NDMM participants.

  2. Change From Baseline in Hemoglobin Levels

    Time frame: Baseline and Cycle 1, days 8 and 15 and Cycle 2 days 1, 8, and 15

  3. Change From Baseline in Platelet Count

    Time frame: Baseline and Cycle 1, days 8 and 15 and Cycle 2 days 1, 8, and 15

  4. Change From Baseline in Neutrophil Count

    Time frame: Baseline and Cycle 1, days 8 and 15 and Cycle 2 days 1, 8, and 15

  5. Change From Baseline in Bilirubin

    Time frame: Baseline and Cycle 2 day 1

  6. Change From Baseline in Creatinine

    Time frame: Baseline and Cycle 1, days 8 and 15 and Cycle 2 days 1, 8, and 15

Secondary outcomes

  1. Maximum Plasma Concentration of Carfilzomib on Day 8 of Cycle 1 by Dose Group

    Time frame: Day 8 of Cycle 1 at predose, 15 minutes after the start of infusion, at the end of infusion, and 15 and 60 minutes after the end of infusion

  2. Time to Maximum Plasma Concentration of Carfilzomib on Day 8 of Cycle 1 by Dose Group

    Time frame: Day 8 of Cycle 1 at predose, 15 minutes after the start of infusion, at the end of infusion, and 15 and 60 minutes after the end of infusion

  3. Area Under the Curve From Time Zero to Time of Last Quantifiable Concentration of Carfilzomib on Day 8 of Cycle 1 by Dose Group

    Time frame: Day 8 of Cycle 1 at predose, 15 minutes after the start of infusion, at the end of infusion, and 15 and 60 minutes after the end of infusion

  4. Overall Response Rate (ORR)

    Response was determined by the investigator based on the International Myeloma Working Group Uniform Response Criteria (IMWG URC). ORR was defined as the percentage of participants who achieved a best response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR) or partial response (PR). Responses must have been confirmed in 2 consecutive assessments at any time prior to initiation of any new therapy. Disease assessments included serum protein electrophoresis (SPEP) with immunofixation, urine protein electrophoresis (UPEP; 24-hour assessment) with immunofixation, serum free light chain (SFLC), quantitative immunoglobulins, bone marrow aspirates to determine percent plasma cell involvement, and skeletal imaging for plasmacytoma evaluation.

    Time frame: Response assessments were performed on day 1 of each treatment cycle from cycle 2 and then every 8 weeks during follow-up until disease progression. Median time on follow-up was 10.6 months in RRMM participants and 6.9 months in NDMM participants.

  5. Complete Response Rate (CRR)

    Complete Response Rate (CRR) is defined as the percentage of participants who achieved a best overall response of either stringent complete response (sCR) or complete response (CR) in accordance with International Myeloma Working Group-Uniform Response Criteria (IMWG-URC). sCR: As for CR, and absence of clonal plasma cells in bone marrow (BM) CR: Negative serum and urine immunofixation, disappearance of any soft tissue plasmacytomas, \< 5% plasma cells in BM, and normal SFLC ratio in participants with measurable disease only by SFLC.

    Time frame: Response assessments were performed on day 1 of each treatment cycle from cycle 2 and then every 8 weeks during follow-up until disease progression. Median time on follow-up was 10.6 months in RRMM participants and 6.9 months in NDMM participants.

  6. Progression-free Survival (PFS)

    PFS is defined as the time from the first day of study treatment to the earlier of disease progression or death due to any cause. Disease progression was determined by the investigator according to IMWG-URC. Progressive Disease (PD): Increase of 25% from lowest value in serum M-component (absolute increase ≥ 0.5 g/dL), urine M-component (absolute increase ≥ 200 mg per 24 hours) and/or the difference between involved and uninvolved FLC levels (absolute increase \>10 mg/dL) in patients without measurable serum and urine M-protein levels, and/or any new or increase in size of bone lesions or soft tissue plasmacytomas, or development of hypercalcemia. PFS was analyzed using Kaplan-Meier methods. Participants who were alive with no documented PD, started new anticancer therapy before documentation of PD or death, had death or PD immediately after \> 1 consecutively missed assessment visit, were lost to follow-up or withdrew consent were censored at the date of last disease assessment.

    Time frame: From first dose of study drug until the end of follow-up; Median time on follow-up was 10.6 months in RRMM participants and 6.9 months in NDMM participants.

  7. Duration of Response (DOR)

    Duration of response (DOR) was calculated for participants who achieved a confirmed PR or better based on Investigator assessment and according to the IMWG URC. Duration of overall response is defined as the time from first documentation of response to disease progression or death due to any cause. DOR was analyzed using Kaplan-Meier methods. Participants who were alive with no documented PD, started new anticancer therapy before documentation of PD or death, had death or PD immediately after \> 1 consecutively missed disease assessment visit, were lost to follow-up, or withdrew consent were censored at the date of last disease assessment.

    Time frame: From first dose of study drug until the end of follow-up; Median time on follow-up was 10.6 months in RRMM participants and 6.9 months in NDMM participants.

07

Results

Posted Nov 6, 2020

Participant flow

This study was conducted at 21 centers in the United States. The study had 2 parts: dose-evaluation and dose-expansion.

Participant flow — Overall Study
MilestoneRRMM Dose-evaluation: Carfilzomib 56 mg/m²RRMM Dose-evaluation: Carfilzomib 70 mg/m²RRMM Dose-expansion: Carfilzomib 70 mg/m²NDMM Dose-evaluation: Carfilzomib 56/70 mg/m²NDMM Dose-expansion: Carfilzomib 70 mg/m²NDMM Dose-expansion: Carfilzomib 56 mg/m²
Started1012349933
Completed232011
Not completed89329832
Withdrew: Sponsor decision001101
Withdrew: Withdrawal by subject322139
Withdrew: Death002000
Withdrew: Lost to follow-up000001
Withdrew: Protocol specified criteria57277521

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs)

Safety and tolerability were evaluated according to the type, incidence, and severity of adverse events. An AE is defined as any untoward medical occurrence in a clinical trial subject. The event does not necessarily have a causal relationship with study treatment. A serious adverse event is defined as an AE that meets at least 1 of the following serious criteria: * fatal * life threatening * requires in-patient hospitalization or prolongation of existing hospitalization * results in persistent or significant disability/incapacity * congenital anomaly/birth defect * other medically important serious event The severity of each AE was assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03 where Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life-threatening, and Grade 5 = Death.

Time frame:
From the first dose of any study drug up to 30 days after the last dose of any study drug; median (range) duration of treatment with carfilzomib was 32 (1.1, 76.7) weeks in RRMM participants and 26 (1.0, 94.4) weeks in NDMM participants.
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsRRMM Dose-evaluation: Carfilzomib 56 mg/m²RRMM Dose-evaluation: Carfilzomib 70 mg/m²RRMM Dose-expansion: Carfilzomib 70 mg/m²NDMM Dose-evaluation: Carfilzomib 56/70 mg/m²NDMM Dose-expansion: Carfilzomib 70 mg/m²NDMM Dose-expansion: Carfilzomib 56 mg/m²
Any adverse event (AE)1012349933
AE Grade ≥ 379235621
Serious adverse events45103311
AEs leading to discontinuation of carfilzomib125021
AEs leading to discontinuation of lenalidomide125022
AEs leading to discontinuation of dexamethasone125022
Fatal adverse events002000
Treatment-related adverse events (TRAE)911309932
Treatment-related AEs Grade ≥ 368185518
Treatment-related serious adverse events126138
TRAEs leading to discontinuation of carfilzomib115021
TRAEs leading to discontinuation of lenalidomide115022
TRAEs leading to discontinuation of dexamethasone115022
Treatment-related fatal adverse events002000
PrimaryChange From Baseline in Hemoglobin Levels
Time frame:
Baseline and Cycle 1, days 8 and 15 and Cycle 2 days 1, 8, and 15
Reported as:
Mean · g/L
Change From Baseline in Hemoglobin Levels
g/LRRMM Dose-evaluation: Carfilzomib 56 mg/m²RRMM Dose-evaluation: Carfilzomib 70 mg/m²RRMM Dose-expansion: Carfilzomib 70 mg/m²NDMM Dose-evaluation: Carfilzomib 56/70 mg/m²NDMM Dose-expansion: Carfilzomib 70 mg/m²NDMM Dose-expansion: Carfilzomib 56 mg/m²
Baseline116.90 ± 14.58120.67 ± 13.51123.24 ± 16.57111.50 ± 18.04120.00 ± 20.96113.21 ± 16.66
Change from Baseline to Cycle 1 Day 8-1.50 ± 7.52-3.33 ± 6.39-0.91 ± 5.46-1.25 ± 8.17-5.56 ± 6.11-1.82 ± 7.21
Change from Baseline to Cycle 1 Day 15-6.90 ± 8.61-9.50 ± 6.29-5.10 ± 7.88-1.75 ± 12.70-6.50 ± 10.20-5.64 ± 9.10
Change from Baseline to Cycle 2 Day 1-5.70 ± 9.78-9.25 ± 8.67-7.38 ± 7.76-3.75 ± 12.65-3.29 ± 9.602.19 ± 10.59
Change from Baseline to Cycle 2 Day 8-6.00 ± 11.91-8.17 ± 9.00-5.59 ± 8.35-0.13 ± 14.64-2.86 ± 8.494.19 ± 12.41
Change from Baseline to Cycle 2 Day 15-8.50 ± 12.47-11.33 ± 8.04-8.45 ± 10.080.00 ± 14.05-5.14 ± 13.582.97 ± 13.04
PrimaryChange From Baseline in Platelet Count
Time frame:
Baseline and Cycle 1, days 8 and 15 and Cycle 2 days 1, 8, and 15
Reported as:
Mean · 10^9 cells/L
Change From Baseline in Platelet Count
10^9 cells/LRRMM Dose-evaluation: Carfilzomib 56 mg/m²RRMM Dose-evaluation: Carfilzomib 70 mg/m²RRMM Dose-expansion: Carfilzomib 70 mg/m²NDMM Dose-evaluation: Carfilzomib 56/70 mg/m²NDMM Dose-expansion: Carfilzomib 70 mg/m²NDMM Dose-expansion: Carfilzomib 56 mg/m²
Baseline151.60 ± 54.40202.50 ± 67.13172.38 ± 33.70214.00 ± 79.22242.89 ± 99.24233.03 ± 67.76
Change from Baseline to Cycle 1 Day 8-12.90 ± 29.88-49.50 ± 58.90-17.36 ± 21.752.38 ± 63.66-51.11 ± 42.10-21.42 ± 36.40
Change from Baseline to Cycle 1 Day 15-58.60 ± 32.76-66.83 ± 87.14-66.39 ± 38.30-23.25 ± 116.67-101.88 ± 84.66-53.39 ± 43.60
Change from Baseline to Cycle 2 Day 155.00 ± 38.6168.67 ± 84.6244.84 ± 52.82141.75 ± 92.68152.00 ± 244.50111.06 ± 84.26
Change from Baseline to Cycle 2 Day 8-44.10 ± 38.14-74.75 ± 86.91-71.06 ± 37.93-28.00 ± 111.10-106.29 ± 130.18-52.78 ± 60.70
Change from Baseline to Cycle 2 Day 15-44.40 ± 21.48-63.25 ± 72.53-60.13 ± 43.37-21.25 ± 82.11-76.14 ± 116.02-44.19 ± 64.73
PrimaryChange From Baseline in Neutrophil Count
Time frame:
Baseline and Cycle 1, days 8 and 15 and Cycle 2 days 1, 8, and 15
Reported as:
Mean · 10^9 cells/L
Change From Baseline in Neutrophil Count
10^9 cells/LRRMM Dose-evaluation: Carfilzomib 56 mg/m²RRMM Dose-evaluation: Carfilzomib 70 mg/m²RRMM Dose-expansion: Carfilzomib 70 mg/m²NDMM Dose-evaluation: Carfilzomib 56/70 mg/m²NDMM Dose-expansion: Carfilzomib 70 mg/m²NDMM Dose-expansion: Carfilzomib 56 mg/m²
Baseline2.53 ± 1.013.40 ± 1.542.72 ± 0.943.04 ± 0.733.24 ± 2.243.26 ± 1.46
Change from Baseline to Cycle 1 Day 80.02 ± 0.820.03 ± 1.870.97 ± 1.190.59 ± 1.20-0.19 ± 1.250.37 ± 1.29
Change from Baseline to Cycle 1 Day 150.28 ± 1.14-0.09 ± 1.940.81 ± 1.091.08 ± 1.530.43 ± 1.830.09 ± 1.48
Change from Baseline to Cycle 2 Day 10.36 ± 1.99-0.33 ± 1.590.16 ± 1.150.02 ± 0.580.09 ± 2.460.18 ± 0.95
Change from Baseline to Cycle 2 Day 80.18 ± 0.68-0.67 ± 1.280.63 ± 1.080.57 ± 1.050.46 ± 2.490.41 ± 1.25
Change from Baseline to Cycle 2 Day 15-0.30 ± 0.71-0.54 ± 1.69-0.06 ± 1.250.33 ± 0.530.56 ± 2.920.42 ± 2.00
PrimaryChange From Baseline in Bilirubin
Time frame:
Baseline and Cycle 2 day 1
Reported as:
Mean · µmol/L
Change From Baseline in Bilirubin
µmol/LRRMM Dose-evaluation: Carfilzomib 56 mg/m²RRMM Dose-evaluation: Carfilzomib 70 mg/m²RRMM Dose-expansion: Carfilzomib 70 mg/m²NDMM Dose-evaluation: Carfilzomib 56/70 mg/m²NDMM Dose-expansion: Carfilzomib 70 mg/m²NDMM Dose-expansion: Carfilzomib 56 mg/m²
Baseline8.55 ± 3.789.98 ± 4.729.10 ± 4.7610.26 ± 4.386.84 ± 4.017.16 ± 3.29
Change from Baseline to Cycle 2 Day 10.86 ± 3.251.00 ± 3.681.34 ± 3.523.42 ± 5.560.49 ± 2.911.21 ± 3.10
PrimaryChange From Baseline in Creatinine
Time frame:
Baseline and Cycle 1, days 8 and 15 and Cycle 2 days 1, 8, and 15
Reported as:
Mean · µmol/L
Change From Baseline in Creatinine
µmol/LRRMM Dose-evaluation: Carfilzomib 56 mg/m²RRMM Dose-evaluation: Carfilzomib 70 mg/m²RRMM Dose-expansion: Carfilzomib 70 mg/m²NDMM Dose-evaluation: Carfilzomib 56/70 mg/m²NDMM Dose-expansion: Carfilzomib 70 mg/m²NDMM Dose-expansion: Carfilzomib 56 mg/m²
Baseline80.18 ± 18.5782.88 ± 22.0179.09 ± 17.6175.80 ± 7.7895.37 ± 41.1780.60 ± 21.56
Change from Baseline to Cycle 1 Day 8-2.65 ± 5.05-5.30 ± 10.292.09 ± 8.31-1.22 ± 8.25-8.51 ± 29.44-0.22 ± 12.89
Change from Baseline to Cycle 1 Day 15-4.42 ± 7.92-4.60 ± 11.32-1.85 ± 12.693.65 ± 27.2929.39 ± 130.240.42 ± 17.59
Change from Baseline to Cycle 2 Day 1-3.80 ± 6.81-7.74 ± 11.98-1.44 ± 9.66-10.39 ± 10.05-17.17 ± 36.71-4.31 ± 9.84
Change from Baseline to Cycle 2 Day 8-6.45 ± 4.97-11.09 ± 12.701.85 ± 10.95-12.27 ± 8.20-20.08 ± 37.86-4.32 ± 9.36
Change from Baseline to Cycle 2 Day 15-6.28 ± 10.29-13.26 ± 9.054.88 ± 13.78-12.38 ± 6.90-21.85 ± 39.17-1.99 ± 18.08
SecondaryMaximum Plasma Concentration of Carfilzomib on Day 8 of Cycle 1 by Dose Group
Time frame:
Day 8 of Cycle 1 at predose, 15 minutes after the start of infusion, at the end of infusion, and 15 and 60 minutes after the end of infusion
Reported as:
Mean · ng/mL
Maximum Plasma Concentration of Carfilzomib on Day 8 of Cycle 1 by Dose Group
ng/mLCarfilzomib 56 mg/m²Carfilzomib 70 mg/m²
Maximum Plasma Concentration of Carfilzomib on Day 8 of Cycle 1 by Dose Group11700 ± 6730012400 ± 45000
SecondaryTime to Maximum Plasma Concentration of Carfilzomib on Day 8 of Cycle 1 by Dose Group
Time frame:
Day 8 of Cycle 1 at predose, 15 minutes after the start of infusion, at the end of infusion, and 15 and 60 minutes after the end of infusion
Reported as:
Median · hours
Time to Maximum Plasma Concentration of Carfilzomib on Day 8 of Cycle 1 by Dose Group
hoursCarfilzomib 56 mg/m²Carfilzomib 70 mg/m²
Time to Maximum Plasma Concentration of Carfilzomib on Day 8 of Cycle 1 by Dose Group0.28 (0.17 to 24)0.27 (0.17 to 0.68)
SecondaryArea Under the Curve From Time Zero to Time of Last Quantifiable Concentration of Carfilzomib on Day 8 of Cycle 1 by Dose Group
Time frame:
Day 8 of Cycle 1 at predose, 15 minutes after the start of infusion, at the end of infusion, and 15 and 60 minutes after the end of infusion
Reported as:
Mean · hr*ng/mL
Area Under the Curve From Time Zero to Time of Last Quantifiable Concentration of Carfilzomib on Day 8 of Cycle 1 by Dose Group
hr*ng/mLCarfilzomib 56 mg/m²Carfilzomib 70 mg/m²
Area Under the Curve From Time Zero to Time of Last Quantifiable Concentration of Carfilzomib on Day 8 of Cycle 1 by Dose Group4150 ± 175009130 ± 32800
SecondaryOverall Response Rate (ORR)

Response was determined by the investigator based on the International Myeloma Working Group Uniform Response Criteria (IMWG URC). ORR was defined as the percentage of participants who achieved a best response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR) or partial response (PR). Responses must have been confirmed in 2 consecutive assessments at any time prior to initiation of any new therapy. Disease assessments included serum protein electrophoresis (SPEP) with immunofixation, urine protein electrophoresis (UPEP; 24-hour assessment) with immunofixation, serum free light chain (SFLC), quantitative immunoglobulins, bone marrow aspirates to determine percent plasma cell involvement, and skeletal imaging for plasmacytoma evaluation.

Time frame:
Response assessments were performed on day 1 of each treatment cycle from cycle 2 and then every 8 weeks during follow-up until disease progression. Median time on follow-up was 10.6 months in RRMM participants and 6.9 months in NDMM participants.
Reported as:
Number · percentage of participants
Overall Response Rate (ORR)
percentage of participantsRRMM Dose-evaluation: Carfilzomib 56 mg/m²RRMM Dose-evaluation: Carfilzomib 70 mg/m²RRMM Dose-expansion: Carfilzomib 70 mg/m²RRMM: Combined Carfilzomib 70 mg/m²NDMM Dose-evaluation: Carfilzomib 56/70 mg/m²NDMM Dose-expansion: Carfilzomib 70 mg/m²NDMM: Combined Carfilzomib 70 mg/m²NDMM Dose-expansion: Carfilzomib 56 mg/m²
Overall Response Rate (ORR)90.0 (55.5 to 99.7)91.7 (61.5 to 99.8)88.2 (72.5 to 96.7)89.1 (76.4 to 96.4)88.9 (51.8 to 99.7)77.8 (40.0 to 97.2)83.3 (58.6 to 96.4)97.0 (84.2 to 99.9)
SecondaryComplete Response Rate (CRR)

Complete Response Rate (CRR) is defined as the percentage of participants who achieved a best overall response of either stringent complete response (sCR) or complete response (CR) in accordance with International Myeloma Working Group-Uniform Response Criteria (IMWG-URC). sCR: As for CR, and absence of clonal plasma cells in bone marrow (BM) CR: Negative serum and urine immunofixation, disappearance of any soft tissue plasmacytomas, \< 5% plasma cells in BM, and normal SFLC ratio in participants with measurable disease only by SFLC.

Time frame:
Response assessments were performed on day 1 of each treatment cycle from cycle 2 and then every 8 weeks during follow-up until disease progression. Median time on follow-up was 10.6 months in RRMM participants and 6.9 months in NDMM participants.
Reported as:
Number · percentage of participants
Complete Response Rate (CRR)
percentage of participantsRRMM Dose-evaluation: Carfilzomib 56 mg/m²RRMM Dose-evaluation: Carfilzomib 70 mg/m²RRMM Dose-expansion: Carfilzomib 70 mg/m²RRMM: Combined Carfilzomib 70 mg/m²NDMM Dose-evaluation: Carfilzomib 56/70 mg/m²NDMM Dose-expansion: Carfilzomib 70 mg/m²NDMM: Combined Carfilzomib 70 mg/m²NDMM Dose-expansion: Carfilzomib 56 mg/m²
Complete Response Rate (CRR)20.0 (2.5 to 55.6)16.7 (2.1 to 48.4)26.5 (12.9 to 44.4)23.9 (12.6 to 38.8)22.2 (2.8 to 60.0)11.1 (0.3 to 48.2)16.7 (3.6 to 41.4)33.3 (18.0 to 51.8)
SecondaryProgression-free Survival (PFS)

PFS is defined as the time from the first day of study treatment to the earlier of disease progression or death due to any cause. Disease progression was determined by the investigator according to IMWG-URC. Progressive Disease (PD): Increase of 25% from lowest value in serum M-component (absolute increase ≥ 0.5 g/dL), urine M-component (absolute increase ≥ 200 mg per 24 hours) and/or the difference between involved and uninvolved FLC levels (absolute increase \>10 mg/dL) in patients without measurable serum and urine M-protein levels, and/or any new or increase in size of bone lesions or soft tissue plasmacytomas, or development of hypercalcemia. PFS was analyzed using Kaplan-Meier methods. Participants who were alive with no documented PD, started new anticancer therapy before documentation of PD or death, had death or PD immediately after \> 1 consecutively missed assessment visit, were lost to follow-up or withdrew consent were censored at the date of last disease assessment.

Time frame:
From first dose of study drug until the end of follow-up; Median time on follow-up was 10.6 months in RRMM participants and 6.9 months in NDMM participants.
Reported as:
Median · months
Progression-free Survival (PFS)
monthsRRMM Dose-evaluation: Carfilzomib 56 mg/m²RRMM Dose-evaluation: Carfilzomib 70 mg/m²RRMM Dose-expansion: Carfilzomib 70 mg/m²RRMM: Combined Carfilzomib 70 mg/m²NDMM Dose-evaluation: Carfilzomib 56/70 mg/m²NDMM Dose-expansion: Carfilzomib 70 mg/m²NDMM: Combined Carfilzomib 70 mg/m²NDMM Dose-expansion: Carfilzomib 56 mg/m²
Progression-free Survival (PFS)NA (14.8 to NA)NA (5.6 to NA)NA (21.1 to NA)NA (21.1 to NA)NA (4.7 to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryDuration of Response (DOR)

Duration of response (DOR) was calculated for participants who achieved a confirmed PR or better based on Investigator assessment and according to the IMWG URC. Duration of overall response is defined as the time from first documentation of response to disease progression or death due to any cause. DOR was analyzed using Kaplan-Meier methods. Participants who were alive with no documented PD, started new anticancer therapy before documentation of PD or death, had death or PD immediately after \> 1 consecutively missed disease assessment visit, were lost to follow-up, or withdrew consent were censored at the date of last disease assessment.

Time frame:
From first dose of study drug until the end of follow-up; Median time on follow-up was 10.6 months in RRMM participants and 6.9 months in NDMM participants.
Reported as:
Median · months
Duration of Response (DOR)
monthsRRMM Dose-evaluation: Carfilzomib 56 mg/m²RRMM Dose-evaluation: Carfilzomib 70 mg/m²RRMM Dose-expansion: Carfilzomib 70 mg/m²RRMM: Combined Carfilzomib 70 mg/m²NDMM Dose-evaluation: Carfilzomib 56/70 mg/m²NDMM Dose-expansion: Carfilzomib 70 mg/m²NDMM: Combined Carfilzomib 70 mg/m²NDMM Dose-expansion: Carfilzomib 56 mg/m²
Duration of Response (DOR)NA (NA to NA)NA (11.6 to NA)NA (20.2 to NA)NA (20.2 to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)

Adverse events

Collected over All-cause Mortality is reported from the enrollment date up to the end of study; maximum time on study was 30.6 months. Treatment-emergent adverse events are reported from the first dose of any study drug up to 30 days after the last dose of any study drug; median (range) duration of treatment with carfilzomib was 32 (1.1, 76.7) weeks in RRMM participants and 26 (1.0, 94.4) weeks in NDMM participants.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
RRMM Dose-evaluation: Carfilzomib 56 mg/m²0/10 (0%)4/10 (40%)10/10 (100%)
RRMM Dose-evaluation: Carfilzomib 70 mg/m²0/12 (0%)5/12 (41.7%)12/12 (100%)
RRMM Dose-expansion: Carfilzomib 70 mg/m²2/34 (5.9%)10/34 (29.4%)33/34 (97.1%)
NDMM Dose-evaluation: Carfilzomib 56/70 mg/m²0/9 (0%)3/9 (33.3%)9/9 (100%)
NDMM Dose-expansion: Carfilzomib 70 mg/m²0/9 (0%)3/9 (33.3%)9/9 (100%)
NDMM Dose-expansion: Carfilzomib 56 mg/m²0/33 (0%)11/33 (33.3%)33/33 (100%)
Most frequent serious events
Showing 10 of 44
Most frequent serious events
EventRRMM Dose-evaluation: Carfilzomib 56 mg/m²RRMM Dose-evaluation: Carfilzomib 70 mg/m²RRMM Dose-expansion: Carfilzomib 70 mg/m²NDMM Dose-evaluation: Carfilzomib 56/70 mg/m²NDMM Dose-expansion: Carfilzomib 70 mg/m²NDMM Dose-expansion: Carfilzomib 56 mg/m²
Thrombotic microangiopathyBlood and lymphatic system disorders0/100/120/340/92/90/33
Cardiac failure congestiveCardiac disorders0/100/120/340/92/90/33
Pleural effusionRespiratory, thoracic and mediastinal disorders0/102/120/340/90/90/33
ThrombocytopeniaBlood and lymphatic system disorders0/100/120/340/91/90/33
Angina pectorisCardiac disorders0/100/120/341/90/90/33
Systemic inflammatory response syndromeGeneral disorders0/100/120/341/90/90/33
Spinal compression fractureInjury, poisoning and procedural complications0/100/120/341/90/90/33
Pulmonary oedemaRespiratory, thoracic and mediastinal disorders0/100/120/340/91/90/33
Device related infectionInfections and infestations1/100/120/340/90/90/33
Acute kidney injuryRenal and urinary disorders1/101/120/340/90/91/33
Most frequent other events
Showing 10 of 247
Most frequent other events
EventRRMM Dose-evaluation: Carfilzomib 56 mg/m²RRMM Dose-evaluation: Carfilzomib 70 mg/m²RRMM Dose-expansion: Carfilzomib 70 mg/m²NDMM Dose-evaluation: Carfilzomib 56/70 mg/m²NDMM Dose-expansion: Carfilzomib 70 mg/m²NDMM Dose-expansion: Carfilzomib 56 mg/m²
DiarrhoeaGastrointestinal disorders5/106/1218/347/96/916/33
FatigueGeneral disorders5/104/1221/343/94/913/33
ConstipationGastrointestinal disorders3/107/127/345/92/910/33
Upper respiratory tract infectionInfections and infestations3/107/1214/343/91/915/33
HeadacheNervous system disorders1/103/128/343/95/913/33
NauseaGastrointestinal disorders5/102/1212/342/94/917/33
InsomniaPsychiatric disorders4/103/127/342/90/917/33
ThrombocytopeniaBlood and lymphatic system disorders5/104/126/340/91/91/33
PyrexiaGeneral disorders5/102/125/341/93/96/33
Muscle spasmsMusculoskeletal and connective tissue disorders2/106/1210/342/93/98/33

Baseline characteristics

All enrolled participants

Age, Continuous
Age, Continuous(years)RRMM Dose-evaluation: Carfilzomib 56 mg/m²RRMM Dose-evaluation: Carfilzomib 70 mg/m²RRMM Dose-expansion: Carfilzomib 70 mg/m²NDMM Dose-evaluation: Carfilzomib 56/70 mg/m²NDMM Dose-expansion: Carfilzomib 70 mg/m²NDMM Dose-expansion: Carfilzomib 56 mg/m²Total
Mean67.4 ± 9.366.4 ± 8.161.9 ± 11.259.0 ± 14.061.8 ± 6.560.4 ± 10.761.7 ± 10.6
Age, Customized
Age, Customized(Participants)RRMM Dose-evaluation: Carfilzomib 56 mg/m²RRMM Dose-evaluation: Carfilzomib 70 mg/m²RRMM Dose-expansion: Carfilzomib 70 mg/m²NDMM Dose-evaluation: Carfilzomib 56/70 mg/m²NDMM Dose-expansion: Carfilzomib 70 mg/m²NDMM Dose-expansion: Carfilzomib 56 mg/m²Total
< 65 years4520662364
65 to 74 years561033936
≥ 75 years1140017
Sex: Female, Male
Sex: Female, Male(Participants)RRMM Dose-evaluation: Carfilzomib 56 mg/m²RRMM Dose-evaluation: Carfilzomib 70 mg/m²RRMM Dose-expansion: Carfilzomib 70 mg/m²NDMM Dose-evaluation: Carfilzomib 56/70 mg/m²NDMM Dose-expansion: Carfilzomib 70 mg/m²NDMM Dose-expansion: Carfilzomib 56 mg/m²Total
Female3515331645
Male7719661762
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)RRMM Dose-evaluation: Carfilzomib 56 mg/m²RRMM Dose-evaluation: Carfilzomib 70 mg/m²RRMM Dose-expansion: Carfilzomib 70 mg/m²NDMM Dose-evaluation: Carfilzomib 56/70 mg/m²NDMM Dose-expansion: Carfilzomib 70 mg/m²NDMM Dose-expansion: Carfilzomib 56 mg/m²Total
Hispanic or Latino0130217
Not Hispanic or Latino101030973096
Unknown or Not Reported0110024
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)RRMM Dose-evaluation: Carfilzomib 56 mg/m²RRMM Dose-evaluation: Carfilzomib 70 mg/m²RRMM Dose-expansion: Carfilzomib 70 mg/m²NDMM Dose-evaluation: Carfilzomib 56/70 mg/m²NDMM Dose-expansion: Carfilzomib 70 mg/m²NDMM Dose-expansion: Carfilzomib 56 mg/m²Total
Asian1110014
Black or African American14421214
Native Hawaiian or Other Pacific Islander0010001
White8724772881
Other0040127
08

Study locations

59 sites
  • Research Site
    Bakersfield, California 93309, United States
  • CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center
    Bakersfield, California, United States
  • Research Site
    Burbank, California 91505, United States
  • Providence Saint Joseph Medical Center
    Burbank, California, United States
  • Research Site
    Fountain Valley, California 92708, United States
  • Compassionate Care Research Group, Inc.
    Fountain Valley, California, United States
  • Research Site
    Los Angeles, California 90017, United States
  • Research Site
    Los Angeles, California 90095-1686, United States
  • Los Angeles Hematology / Oncology Medical Group
    Los Angeles, California, United States
  • Research Site
    Whittier, California 90603, United States
  • Research Site
    Aurora, Colorado 80045, United States
  • University of Colorado
    Aurora, Colorado, United States
  • Research Site
    Washington, District of Columbia 20057, United States
  • Lombardi Cancer Center, Pediatric Hematology Oncology
    Washington, District of Columbia, United States
  • Research Site
    Fort Myers, Florida 33905, United States
  • Florida Cancer Specialists
    Fort Myers, Florida, United States
  • Research Site
    Tampa, Florida 33612, United States
  • H. Lee Moffitt Cancer Center & Research Institute
    Tampa, Florida, United States
  • Research Site
    West Palm Beach, Florida 33401, United States
  • Florida Cancer Specialists
    West Palm Beach, Florida, United States
  • University of Chicago Medical Center
    Chicago, Illinois, United States
  • Research Site
    Boston, Massachusetts 02114, United States
  • Dana Farber Partners Cancer Care
    Boston, Massachusetts, United States
  • Research Site
    Ann Arbor, Michigan 48109, United States
  • Research Site
    Hackensack, New Jersey 07601, United States
  • John Theurer Cancer Center at Hackensack University Medical Center
    Hackensack, New Jersey, United States
  • Research Site
    New York, New York 10021, United States
  • Research Site
    New York, New York 10065, United States
  • Clinical Research Alliance
    New York, New York, United States
  • Memorial Sloan Kettering
    New York, New York, United States
  • Morton Coleman, MD
    New York, New York, United States
  • Weill Cornell Medical College
    New York, New York, United States
  • Research Site
    Stony Brook, New York 11794, United States
  • Stony Brook University Medical Center
    Stony Brook, New York, United States
  • Research Site
    Durham, North Carolina 27705, United States
  • Durham Veterans Affairs Medical Center
    Durham, North Carolina, United States
  • Research Site
    Cincinnati, Ohio 45242, United States
  • Sarah Cannon Research Institute
    Cincinnati, Ohio, United States
  • Research Site
    Bend, Oregon 97701, United States
  • Bend Memorial Clinic
    Bend, Oregon, United States
  • Research Site
    Charleston, South Carolina 29424, United States
  • Medical University of South Carolina, Hollings Cancer Center
    Charleston, South Carolina, United States
  • Research Site
    Greenville, South Carolina 29607, United States
  • Greenville Health System
    Greenville, South Carolina, United States
  • Saint Francis Hospital Cancer Center
    Greenville, South Carolina, United States
  • Research Site
    Sioux Falls, South Dakota 57105, United States
  • Avera Cancer Institute
    Sioux Falls, South Dakota, United States
  • Research Site
    Germantown, Tennessee 38138, United States
  • The West Clinic, PC
    Memphis, Tennessee, United States
  • Research Site
    Nashville, Tennessee 37203, United States
  • Research Site
    Nashville, Tennessee 37232, United States
  • Tennessee Oncology, PLLC / The Sarah Cannon Research lnstitute
    Nashville, Tennessee, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee, United States
  • Research Site
    Salt Lake City, Utah 84112, United States
  • Huntsman Cancer Institute
    Salt Lake City, Utah, United States
  • Research Site
    Seattle, Washington 98104, United States
  • Swedish Cancer Institute
    Seattle, Washington, United States
  • Aurora Health Care, Aurora Cancer Care
    Milwaukee, Wisconsin, United States
  • Research Site
    Wauwatosa, Wisconsin 53226, United States
09

References and documents

Publications

  • Biran N, Siegel D, Berdeja JG, Raje N, Cornell RF, Alsina M, Kovacsovics T, Fang B, Kimball AS, Landgren O. Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study. Am J Hematol. 2019 Jul;94(7):794-802. doi: 10.1002/ajh.25498. Epub 2019 May 13. PubMed 31021005 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2015 to primary completion in Oct 2019, 53 months.

Results were first posted in Nov 2020, 1 year after primary completion.

Of 212 industry-sponsored phase 1 interventional studies under Multiple Myeloma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 71. This study's 53 months is above that.

Counting every sponsor, half of 413 studies reached it within 50 months; a quarter within 33 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2014
First posted
Jan 12, 2015
StartActual
Apr 30, 2015
Primary completionActual
Oct 28, 2019
CompletionActual
Oct 28, 2019
Results first posted
Nov 6, 2020
Last update
Nov 6, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 6, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02335983
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Jan 12, 2015
Start date
Apr 30, 2015
Primary completion
Oct 28, 2019
Completion
Oct 28, 2019
Results posted
Nov 6, 2020
Last update
Nov 6, 2020

Study contacts

Amy Kimball, MD
study director · Amgen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Carfilzomib · Lenalidomide · Dexamethasone

Start the discussion